Treatment Information

Back

Melanoma treatment details. Chemotherapy, Biologic therapy.

Mayo Clinic, Rochester, MN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Rochester, MN
Treatments:Chemotherapy, Biologic therapyHospital:Mayo Clinic
Drugs:Journal:Link
Date:Aug 2012

Description:

Patients:
This phase 2 study involved previously untreated metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 42 patients with a median age of 57 years and 57.1% male. Group B had 51 patients with a median age of 57 years and 56.9% male.

Treatment:
Patients in group A were treated with the chemotherapy agent temozolomide and the biologic therapy agent bevacizumab.

Patients in group B were treated with the chemotherapy agents nab-paclitaxel and carboplatin, as well as the biologic therapy agent bevacizumab.

Toxicities:
There were two treatment-related deaths due to bone marrow suppression and disease progression reported for groupA. Grade 3-4 leukopenia, neutropenia, vomiting, and fatigue were also reported.

The most severe toxicities reported for group B were of grade 4. Grade 3-4 toxicities included neutropenia, leukopenia, thrombocytopenia, anemia, fatigue, and thrombosis.

Results:
The median overall survival rates for groups A and B were 12.3 and 13.9 months, respectively.

Correspondence: Dr. Lisa A. Kottschade; email: [email protected]



Back